Effects of recombinant human activated protein C on the coagulation system: A study with rotational thromboelastometry

Acta Anaesthesiologica Scandinavica

Volumn 52, Issue 9, 2008, Pages 1246-1249

  Nilsson, C U ^b   Hellkvist, P D ^c   Engstrom M ^a  

^a HALMSTAD HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c Landskrona Hospital   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN;

ANALYZER; ANTICOAGULATION; ARTICLE; BLOOD ANALYSIS; BLOOD CLOTTING; BLOOD CLOTTING TIME; CONTROLLED STUDY; DRUG EFFECT; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL; THROMBOELASTOMETRY;

BLOOD COAGULATION; HUMANS; PROTEIN C; RECOMBINANT PROTEINS; THROMBELASTOGRAPHY;

EID: 51749118498     PISSN: 00015172     EISSN: 13996576     Source Type: Journal    
DOI: 10.1111/j.1399-6576.2008.01735.x     Document Type: Article

References (18)

1. Russell JA. Management of sepsis. N Engl J Med 2006 355 : 1699 713.
2. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001 344 : 699 709.
3. Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D, Sundin DP, Giroir B. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007 369 : 836 43.
4. Bernard GR, Margolis BD, Shanies HM, Ely EW, Wheeler AP, Levy H, Wong K, Wright TJ. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest 2004 125 : 2206 16.
5. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005 353 : 1332 41.
6. Macias WL, Yan SB, Williams MD, Um SL, Sandusky GE, Ballard DW, Planquois JM. New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated). Crit Care 2005 9 (Suppl. 4) : 38 45.
7. Koestenberger M, Cvirn G, Gallistl S, Muntean W. Drotrecogin alfa activated (recombinant human activated protein C) in combination with heparin or melagatran: effects on prothrombin time and activated partial thromboplastin time. Blood Coagul Fibrinolysis 2004 15 : 693 7.
8. Koestenberger M, Gallistl S, Muntean W, Leschnik B, Fritsch P, Cvirn G. Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma. Thromb Haemost 2005 94 : 69 74.
9. Brueckmann M, Wizenmann J, Hoffmann U, Seeger M, Bewig B. Clinical and laboratory effects of recombinant human activated protein C in the treatment of a patient with sepsis-induced multiple organ failure. Thromb Res 2003 109 (5-6) : 259 63.
10. Kamal AH, Tefferi A, Pruthi RK. How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc 2007 82 : 864 73.
11. Luddington RJ. Thromboelastography/thromboelastometry. Clin Lab Haematol 2005 27 : 81 90.
12. Essell JH, Martin TJ, Salinas J, Thompson JM, Smith VC. Comparison of thromboelastography to bleeding time and standard coagulation tests in patients after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1993 7 : 410 5.
13. Metcalf K. Thromboelastograph monitoring: a clinical perspective. Nurse Anesth 1990 1 : 33 7.
14. Kheirabadi BS, Crissey JM, Deguzman R, Holcomb JB. In vivo bleeding time and in vitro thromboelastography measurements are better indicators of dilutional hypothermic coagulopathy than prothrombin time. J Trauma 2007 62 : 1352 9 discussion 1359-61.
15. Coppell JA, Thalheimer U, Zambruni A, Triantos CK, Riddell AF, Burroughs AK, Perry DJ. The effects of unfractionated heparin, low molecular weight heparin and danaparoid on the thromboelastogram (TEG): an in-vitro comparison of standard and heparinase-modified TEGs with conventional coagulation assays. Blood Coagul Fibrinolysis 2006 17 : 97 104.
16. Murray DJ, Brosnahan WJ, Pennell B, Kapalanski D, Weiler JM, Olson J. Heparin detection by the activated coagulation time: a comparison of the sensitivity of coagulation tests and heparin assays. J Cardiothorac Vasc Anesth 1997 11 : 24 8.
17. Calatzis A, Fritzsche P, Kling M, Hipp R, Stemberger A. An analysis of the correlation of the roTEG coagulation analyser and the Hellinge thromboelastograph D. Ann Hematol 1996 72 : 87.
18. Shinoda T, Arakura H, Katakura M, Shirota T, Nakagawa S. Usefulness of thromboelastography for dosage monitoring of low molecular weight heparin and unfractionated heparin during hemodialysis. Artif Organs 1990 14 : 413 5.